Dyadic Q2 Results Show Commercial Traction with First Product Sales and 80% Yield Jump
DYAI sits 53% above its 52-week low of $0.655.
Summary
Dyadic reported Q2 2026 results with accelerating commercial momentum. The company shipped six recombinant protein products and generated initial pilot sales for cultivated-meat applications. An 80% productivity increase in recombinant human transferrin strengthens manufacturing economics. Multiple partnerships advanced: Proliant began commercializing Albufree DX, Fermbox Bio scaled orders, and Inzymes confirmed initial sales of bovine chymosin. The C1 platform continues to gain validation through Gates Foundation-funded RSV and malaria programs and rapid pandemic response capabilities. This follows the Nasdaq compliance resolution in July and builds on the Q1 revenue surge, signaling a shift toward recurring commercial revenue. The earnings call at 5:00 pm ET may provide financial specifics and guidance.
At the time of this announcement, DYAI was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $0.65 to $1.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.